ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
1 hedge funds and large institutions have $52 invested in ChemoCentryx, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 212 closing their positions.
100% less funds holding
Funds holding: 217 → 1 (-216)
100% less funds holding in top 10
Funds holding in top 10: 12 → 0 (-12)
100% less capital invested
Capital invested by funds: $3.2B → $52 (-$3.2B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 212
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$311M |
| 2 |
Goldman Sachs
New York
|
-$290M |
| 3 |
BlackRock
New York
|
-$250M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$141M |
| 5 |
State Street
Boston,
Massachusetts
|
-$140M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LC
201
Lindbrook Capital
Calabasas,
California
| – | -$13K | -243 | Closed |
|
|
PA
202
Parallel Advisors
San Francisco,
California
| – | -$7K | -145 | Closed |
|
|
EPM
203
Equitec Proprietary Markets
Chicago,
Illinois
| – | -$5K | -100 | Closed |
|
|
PTC
204
Private Trust Company
Cleveland,
Ohio
| – | -$4K | -85 | Closed |
|
|
S
205
SignatureFD
Atlanta,
Georgia
| – | -$4K | -72 | Closed |
|
206
Rockefeller Capital Management
New York
| – | -$3K | -65 | Closed |
|
|
HR
207
Howe & Rusling
Rochester,
New York
| – | -$3K | -61 | Closed |
|
|
GWS
208
Glassman Wealth Services
Vienna,
Virginia
| – | -$1K | -23 | Closed |
|
|
BIA
209
Bell Investment Advisors
Oakland,
California
| – | -$1K | -20 | Closed |
|
|
AAP
210
Arax Advisory Partners
Denver,
Colorado
| – | -$1K | -18 | Closed |
|
|
EI
211
Ellevest Inc
New York
| – | -$1K | -16 | Closed |
|
CCXI Hedge Fund Activity: Q4 2022 in Review
1 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q4 2022, worth a combined $52 — down 100% from $3.2B a quarter earlier.
Sellers outnumbered buyers: 212 funds closed out of CCXI and 0 opened new positions — a net loss of 212 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $311M sold.
- 1 institutional investor held ChemoCentryx, Inc. (CCXI) as of Q4 2022, down from 217 in Q3 2022.
- Funds reported $52 of ChemoCentryx, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new ChemoCentryx, Inc. positions in Q4 2022 and 212 closed out, a net change of -212 holders.
- The largest ChemoCentryx, Inc. seller in Q4 2022 was Vanguard Group, an estimated $311M sold.
Based on aggregated 13F filings for Q4 2022.